Galaxy Surfactants Q2 FY26: revenue up sharply, profit and margins fall

Revenue growth above 20%EBITDA margin compressionResults View source PDF Explain this filing

GALAXYSURF · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.6%Reaction day

₹2245.00

prior close

₹2222.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-1.5% vs market

Specialty Chemicals peers, median of 86sector-0.3%-1.3% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.3 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.2

15m

-0.1

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.6-0.1-1.5-0.3-1.3

Next day

-4.8-0.2-4.6-0.8-4.0

-2.4+0.4-2.9-0.8-1.6

-4.9-0.4-4.5-2.2-2.7

-6.0-0.6-5.4-2.7-3.3

-6.0-0.9-5.1-2.9-3.2

-9.7-3.0-6.7-4.9-4.8

15d

-10.2-3.9-6.4-5.9-4.3

-11.6-4.8-6.7-6.3-5.2

-16.6-7.8-8.8-9.9-6.7

-18.8-7.2-11.6-10.5-8.3

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 86Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Galaxy Surfactants posted Q2 FY26 standalone revenue of Rs 918.97 Cr (up 17.5% YoY) and consolidated revenue of Rs 1,326.17 Cr (up 24.7% YoY). H1 consolidated revenue grew 27.8% YoY. However, profitability fell: standalone PAT dropped to Rs 46.19 Cr from Rs 64.84 Cr; consolidated PAT declined to Rs 66.49 Cr from Rs 84.71 Cr. Standalone EBITDA margins compressed to roughly 9% from 12.7% YoY. Final dividend of Rs 4 per share for FY25 paid during the quarter.

Likely market impact

Strong top line but sharp PAT fall and margin compression may weigh on stock; track margin recovery in coming quarters.